Contribution of STAT3 to Inflammatory and Fibrotic Diseases and Prospects for its Targeting for Treatment

por Kasembeli, Moses M., Bharadwaj, Uddalak, Robinson, Prema, Tweardy, David J.
Publicado en Int J Mol Sci (2018)

Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 To Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution

por Bharadwaj, Uddalak, Kasembeli, Moses M., Robinson, Prema, Tweardy, David J.
Publicado en Pharmacol Rev (2020)

Contribution of chaperones to STAT pathway signaling

por Bocchini, Claire E, Kasembeli, Moses M, Roh, Soung-Hun, Tweardy, David J
Publicado en JAKSTAT (2014)

Chemical Probes that Competitively and Selectively Inhibit Stat3 Activation

por Xu, Xuejun, Kasembeli, Moses M., Jiang, Xueqing, Tweardy, Benjamin J., Tweardy, David J.
Publicado 2009

Chaperonin TRiC/CCT Recognizes Fusion Oncoprotein AML1-ETO through Subunit-Specific Interactions

por Roh, Soung-Hun, Kasembeli, Moses M., Galaz-Montoya, Jesús G., Chiu, Wah, Tweardy, David J.
Publicado en Biophys J (2016)

Monoclonal Antibodies Specific for STAT3β Reveal Its Contribution to Constitutive STAT3 Phosphorylation in Breast Cancer

por Bharadwaj, Uddalak, Kasembeli, Moses M., Eckols, T. Kris, Kolosov, Mikhail, Lang, Paul, Christensen, Kurt, Edwards, Dean P., Tweardy, David J.
Publicado en Cancers (Basel) (2014)

SMALL-MOLECULE TARGETING OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION (STAT) 3 TO TREAT NON-SMALL CELL LUNG CANCER()

por Lewis, Katherine M., Bharadwaj, Uddalak, Eckols, T. Kris, Kolosov, Mikhail, Kasembeli, Moses M., Fridley, Colleen, Siller, Ricardo, Tweardy, David J.
Publicado en Lung Cancer (2015)

Pharmacokinetics and pharmacodynamics of TTI-101, a STAT3 inhibitor that blocks muscle proteolysis in rats with chronic kidney disease

por Zhang, Liping, Wang, Ying, Dong, Yanlan, Chen, Zihong, Eckols, Thomas K., Kasembeli, Moses M., Tweardy, David J., Mitch, William E.
Publicado en Am J Physiol Renal Physiol (2020)

Protein stabilization improves STAT3 function in autosomal dominant hyper-IgE syndrome

por Bocchini, Claire E., Nahmod, Karen, Katsonis, Panagiotis, Kim, Sang, Kasembeli, Moses M., Freeman, Alexandra, Lichtarge, Olivier, Makedonas, George, Tweardy, David J.
Publicado en Blood (2016)

Small-molecule inhibition of STAT3 in radioresistant head and neck squamous cell carcinoma

por Bharadwaj, Uddalak, Eckols, T. Kris, Xu, Xuejun, Kasembeli, Moses M., Chen, Yunyun, Adachi, Makoto, Song, Yongcheng, Mo, Qianxing, Lai, Stephen Y., Tweardy, David J.
Publicado en Oncotarget (2016)

Correction: Small-molecule inhibition of STAT3 in radioresistant head and neck squamous cell carcinoma

por Bharadwaj, Uddalak, Eckols, T. Kris, Xu, Xuejun, Kasembeli, Moses M., Chen, Yunyun, Adachi, Makoto, Song, Yongcheng, Mo, Qianxing, Lai, Stephen Y., Tweardy, David J.
Publicado en Oncotarget (2019)

Rhodium(II) proximity-labeling identifies a novel target site on STAT3 for inhibitors with potent anti-leukemia activity

por Minus, Matthew B., Liu, Wei, Vohidov, Farrukh, Kasembeli, Moses M., Long, Xin, Krueger, Michael, Stevens, Alexandra, Kolosov, Mikhail I., Tweardy, David J., Sison, Edward Allen R., Redell, Michele S., Ball, Zachary T.
Publicado en Angew Chem Int Ed Engl (2015)

Novel STAT3 Small-Molecule Inhibitors Identified by Structure-Based Virtual Ligand Screening Incorporating SH2 Domain Flexibility

por Kong, Ren, Bharadwaj, Uddalak, Eckols, T Kris, Kolosov, Mikhail, Wu, Haoyi, Cruz-Pavlovich, Francisco J. Santa, Shaw, Alison, Ifelayo, Oluwatomilona I., Zhao, Hong, Kasembeli, Moses M., Wong, Stephen T.C., Tweardy, David J
Publicado en Pharmacol Res (2021)

Targeting STAT3 anti-apoptosis pathways with organic and hybrid organic–inorganic inhibitors

por Minus, Matthew B., Wang, Haopei, Munoz, Jaime O., Stevens, Alexandra M., Mangubat-Medina, Alicia E., Krueger, Michael J., Liu, Wei, Kasembeli, Moses M., Cooper, Julian C., Kolosov, Mikhail I., Tweardy, David J., Redell, Michele S., Ball, Zachary T.
Publicado en Org Biomol Chem (2020)

DRUG-REPOSITIONING SCREENING IDENTIFIED PIPERLONGUMINE AS A DIRECT STAT3 INHIBITOR WITH POTENT ACTIVITY AGAINST BREAST CANCER

por Bharadwaj, Uddalak, Eckols, T. Kris, Kolosov, Mikhail, Kasembeli, Moses M., Adam, Abel, Torres, David, Zhang, Xiaomei, Dobrolecki, Lacey E., Wei, Wei, Lewis, Michael T., Dave, Bhuvanesh, Chang, Jenny C., Landis, Melissa D., Creighton, Chad J., Mancini, Michael A., Tweardy, David J.
Publicado 2014